Acute myeloid leukemia (AML) remains the most common form of leukemia and the most common cause of leukemia death. Although conventional chemotherapy can cure between 25 and 45% of AML patients, the majority of patients die after relapse or of complications associated with treatment. Thus, more specific and less toxic treatments for AML patients are needed, especially for elderly patients. An indispensable prerequisite to investigate tailored approaches for AML is the recent progress in the understanding the molecular features that distinguish leukemia progenitors from normal hematopoietic counterparts and the identification of a variety of dysregulated molecular pathways. This in turn would allow the identification of tumor-specific characteristics that provide a rational basis for the development of more tailored, and hence potentially more effective and less toxic, therapeutic approaches. In this review, we describe some of the signaling pathways that are aberrantly regulated in AML, with a specific focus on their pathogenetic and therapeutic significance, and we examine some recent therapies directed against these targets, used in clinical trial for relapsed patients or unfit for conventional chemotherapy.

Palmisano M, Grafone T, Renzulli M, Ottaviani E, Testoni N, Paolini S, et al. (2008). Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. HEMATOLOGY, 13(1), 1-12 [10.1179/102453308X315753].

Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia.

GRAFONE, TIZIANA;OTTAVIANI, EMANUELA;TESTONI, NICOLETTA;PAOLINI, STEFANIA;PAPAYANNIDIS, CRISTINA;BACCARANI, MICHELE;MARTINELLI, GIOVANNI
2008

Abstract

Acute myeloid leukemia (AML) remains the most common form of leukemia and the most common cause of leukemia death. Although conventional chemotherapy can cure between 25 and 45% of AML patients, the majority of patients die after relapse or of complications associated with treatment. Thus, more specific and less toxic treatments for AML patients are needed, especially for elderly patients. An indispensable prerequisite to investigate tailored approaches for AML is the recent progress in the understanding the molecular features that distinguish leukemia progenitors from normal hematopoietic counterparts and the identification of a variety of dysregulated molecular pathways. This in turn would allow the identification of tumor-specific characteristics that provide a rational basis for the development of more tailored, and hence potentially more effective and less toxic, therapeutic approaches. In this review, we describe some of the signaling pathways that are aberrantly regulated in AML, with a specific focus on their pathogenetic and therapeutic significance, and we examine some recent therapies directed against these targets, used in clinical trial for relapsed patients or unfit for conventional chemotherapy.
2008
Palmisano M, Grafone T, Renzulli M, Ottaviani E, Testoni N, Paolini S, et al. (2008). Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. HEMATOLOGY, 13(1), 1-12 [10.1179/102453308X315753].
Palmisano M; Grafone T; Renzulli M; Ottaviani E; Testoni N; Paolini S; Papayannidis C; Baccarani M; Martinelli G
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/68493
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 3
social impact